Pedunculated-type T1 colorectal carcinoma with lung carcinoma metastasis at the deepest invasive portion

2016 ◽  
Vol 9 (4) ◽  
pp. 208-214
Author(s):  
Naoki Asayama ◽  
Shiro Oka ◽  
Shinji Tanaka ◽  
Daiki Hirano ◽  
Kyoku Sumimoto ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Lung Carcinoma ◽  
T1 Colorectal Carcinoma ◽  
Carcinoma Metastasis

Vertical tumor margin of endoscopic resection for T1 colorectal carcinoma affects the prognosis of patients undergoing additional surgery

2022 ◽  
Author(s):  
Tomoyuki Nishimura ◽  
Shiro Oka ◽  
Yuki Kamigaichi ◽  
Hirosato Tamari ◽  
Yasutsugu Shimohara ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Endoscopic Resection ◽  
Tumor Margin ◽  
T1 Colorectal Carcinoma ◽  
Additional Surgery

The Use of Lectins in Biochemical Studies on Colorectal Carcinoma Metastasis

1986 ◽  
pp. 57-72 ◽  
Author(s):  
Tatsuro Irimura ◽  
David M. Ota ◽  
Karen R. Cleary ◽  
Garth L. Nicolson
Keyword(s):  
Colorectal Carcinoma ◽  
Biochemical Studies ◽  
Carcinoma Metastasis

scholarly journals Correction: Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis

2019 ◽  
Vol 10 (10) ◽  
Author(s):  
Ting-Hong Ye ◽  
Fang-Fang Yang ◽  
Yong-Xia Zhu ◽  
Ya-Li Li ◽  
Qian Lei ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Signaling Pathway ◽  
Colony Formation ◽  
Antitumor Immunity ◽  
Vehicle Group ◽  
Stat3 Signaling ◽  
Stat3 Signaling Pathway ◽  
Carcinoma Metastasis

Since publication of this article, the authors have noticed that there were errors in Fig. 1b (the CT 26 cells colony formation images) and Fig. 7c (the vehicle group images). As a result of the misfiling of the data during preparation of figures, incorrect images were inadvertently inserted in these figures. An amendment to this paper has been published and can be accessed via a link at the top of the paper.

scholarly journals EPID-17. ANALYSIS OF THE USE OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi78-vi78
Author(s):  
Catherine Garcia ◽  
Holly Chitwood ◽  
Christopher Harwood ◽  
Brent Shelton ◽  
Rachael Morgan ◽  
...  
Keyword(s):  
United States ◽  
Colorectal Carcinoma ◽  
Lung Carcinoma ◽  
Randomized Clinical Trials ◽  
Small Cell Lung Carcinoma ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Novel Therapy ◽  
Cell Lung Carcinoma

Abstract INTRODUCTION Bevacizumab is an antibody against vascular endothelial growth factor that has been well investigated for glioblastoma, however, has limited proven efficacy. The drug has, however, demonstrated survival benefit in non-small cell lung carcinoma, renal cell carcinoma and colorectal carcinoma. We provide an overview of its use in the United States for select cancers. METHODS We queried the IQVIA database for all cases of glioblastoma diagnosed between January 2014 and June 2018 to analyze the use of bevacizumab for glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma in the United States, and was compared to the standard of care for each indication (temozolomide for glioblastoma, pemetrexed for non-small cell lung carcinoma, and oxaliplatin for colorectal carcinoma). RESULTS A total of 85,351 patients were treated for glioblastoma as captured by IQVIA. Bevacizumab was prescribed in 17,958 patients, with a projected median annual total of 3,718 patients. The use of bevacizumab for glioblastoma during the study period decreased from 2014 to 2018 (p< 0.0001). The use of temozolomide has remained stable since 2014 to 2018 (p=0.49). For non-small cell lung cancer, we saw a significant decrease in the use of both bevacizumab and pemetrexed (p< 0.0001), with bevacizumab being used in less than 2% of the cases since 2017. For colorectal carcinoma, the use of bevacizumab has overall decreased with a peak use in 2016 (p< 0.0001). The use of oxaliplatin has increased (p< 0.0001). CONCLUSIONS Our findings demonstrated a decreased use of bevacizumab in oncology for three indications, likely associated with a changing role due to the benefit of novel therapy such as immunotherapy. The use of bevacizumab has decreased in glioblastoma, that may be associated to the lack of overall survival benefits in randomized clinical trials.

392 Long-Term Outcomes After Treatment for T1 Colorectal Carcinoma - a Multicenter Retrospective Study of Hiroshima GI Endoscopy Research Group -

2016 ◽  
Vol 83 (5) ◽  
pp. AB143
Author(s):  
Yuzuru Tamaru ◽  
Shinji Tanaka ◽  
Shiro Oka ◽  
Shinji Nagata ◽  
Yuko Hiraga ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Colorectal Carcinoma ◽  
Research Group ◽  
Long Term Outcomes ◽  
Gi Endoscopy ◽  
T1 Colorectal Carcinoma

Novel radiomics signature predicts lymph node metastasis in T1 colorectal carcinoma.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 506-506
Author(s):  
Yanlei Ma ◽  
Sheng Zhang ◽  
Xinxiang Li ◽  
Tianye Niu
Keyword(s):  
Lymph Node ◽  
Colorectal Carcinoma ◽  
Receiver Operating Characteristic ◽  
Operating Characteristic ◽  
Characteristic Curve ◽  
Predictive Performance ◽  
Cancer Center ◽  
T1 Colorectal Carcinoma ◽  
Auc Value ◽  
Receiver Operating

506 Background: This study evaluates the predictive performance of radiomic features in metastasis of T1 colorectal carcinoma (CRC) to lymph nodes. Methods: A total of 10 200 CRC patients from our clinical cancer center included in this analysis. 225 eligible cases diagnosed with T1 CRC were included and divided into two groups: computed tomography (CT) image group (n = 82) and magnetic resonance image (MRI) group (n = 143) based on the preoperative image data available. A total of 548 radiomic features were extracted from each case and analyzed, and then a panel of radiomic features associated with lymph node metastases (LNM) were selected using Mann-Whitney U test. Combining these selected radiomic features and clinical data, the predictive performance for LNM was calculated using receiver operating characteristic (ROC) curves. Results: The prediction accuracy for LNM of T1 CRC could be improved to 0.88 by area under the receiver operating characteristic curve (AUC) through integration of one radiomic feature and three clinical indicators in CT group. In the group of contrast enhanced T1-weighted MRI (T1w-MRI), combination of two radiomic features and three clinical parameters present an AUC value of 0.85. In the group of T2-weighted MRI (T2w-MRI), combination of four radiomic features and five clinical characteristics identified T1 tumors with LNM with an AUC value of 0.87. Conclusions: The current study present a good predictive performance of combination of radiomic features with clinic characteristic in identifying T1 CRC with LNM, which may provide an important opportunity for us to make clinical treatment decision-making for T1 CRC patients.

scholarly journals Enhanced Tumour Growth and Impaired Cellular Antitumoural Defence in Hepatic Colorectal Carcinoma Metastasis in Rats after Laparoscopy Compared to Open Surgery

2008 ◽  
Vol 15 (4) ◽  
pp. 1239-1248
Author(s):  
D. Th. Inderbitzin ◽  
G. R. Marti ◽  
S. Eichenberger ◽  
H.- M. Hoogewoud ◽  
L. Kraehenbuehl
Keyword(s):  
Colorectal Carcinoma ◽  
Open Surgery ◽  
Tumour Growth ◽  
Carcinoma Metastasis

101 Endoscopic Resection of High-Risk T1 Colorectal Carcinoma Prior to Surgical Resection Has No Adverse Effect on Long-Term Outcomes

2015 ◽  
Vol 81 (5) ◽  
pp. AB112-AB113
Author(s):  
Anouk Overwater ◽  
Martijn G. Van Oijen ◽  
Aneya Van Den Blink ◽  
Marcel Spanier ◽  
Tom Seerden ◽  
...  
Keyword(s):  
Adverse Effect ◽  
High Risk ◽  
Colorectal Carcinoma ◽  
Surgical Resection ◽  
Endoscopic Resection ◽  
Long Term Outcomes ◽  
T1 Colorectal Carcinoma
Sign in / Sign up

Export Citation Format

Share Document